All the data extracted from the scientific publications is available by clicking here.

Currently, the effectiveness of URODELIA’s technology has been demonstrated in a dozen scientific publications.

Importance of hydroxyapatite particles characteristics on cytokines production by human monocytes in vitro. Laquerriere P., Grandjean-Laquerriere A., Jallot E., Laurent-Maquin D., Frayssinet P., Guenounou M.. Biomaterials. 2003; 24(16): 2739-47

Influence of Hydroxyapatite Particle Characteristics on Behaviour of Human Monocytes In Vitro. Laquerriere P., Grandjean-Laquerriere A., Killian L., Jallot E., Beorchia A., Guenounou M., Frayssinet P., Balossier G. Journal of Biomedical Materials Research. 2004.

Autovaccination against tumors using a mineral/protein composite, Frayssinet Patrick, Cuello-Carion, D., Laquerrière, P., Grandjean-Laquerièrre, A., Ciocca, D., In Radons, J., Multhoff, G., (eds) Heat Shock Proteins in Biology and Medicine, Reasearch Signpost, Kerala 2006.

Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. Grandjean-Laquerrière, A., Tabary, O., Jacquot, J., Richard, D., Frayssinet, P., Guenounou, M., Laurent-Maquin, D., Laquerrière,P., Gangloff, S., Biomaterials. 2007 Jan;28(3):400-4. Epub 2006 Sep 28.,

A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. Ciocca DR, Frayssinet P, Cuello-Carrion FD. Cell Stress Chaperones. 2007 12(1):33-43

NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy, Jin C., Frayssinet P., Pelker R., Cwirka D, Hu B, Vignery A, Eisenbarth S.C., and Flavell R.A., PNAS 2011 108 (36) 14867-14872

Hydroxylapatite (HA) Powder for Autovaccination Against Canine Non Hodgkin’s Lymphoma. Simonet M., Rouquet N. and Frayssinet P, Materials Science » Biomaterials » “Advances in Biomaterials Science and Biomedical Applications“, book edited by Rosario Pignatello, 2012, Rijeka, Croatia, ISBN

Randomized, placebo-controlled, double-blinded chemo-immunotherapy clinical trial in a Pet Dog model of Diffuse Large B-cell Lymphoma: a successful combination. Marconato L., Frayssinet P., Rouquet N., Comazzi S., Leone V.F., Laganga P., Rossi F., Pezzoli L., Aresu L., Clin Cancer Res. 2014 Feb 1;20(3):668-77

Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma Aresu L., Aricò A., Ferraresso S., Martini V., Comazzi S., Riondato F., Giantin M., Dacasto M., Guadagnin E., Frayssinet P., Rouquet N., Drigo M., Marconato L.,. Vet J. 2014 May;200(2):318-24.

Adjuvants minéraux de vaccination en oncologie. P. Frayssinet,. Techniques de l’ingénieur, N4 965 : 1-8 (2014)

Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. L. Marconatoa, D. Stefanellob, S. Sabattinic, S. Comazzib, F. Riondatod, P. Lagangaa,P. Frayssinet, S. Pizzonia, N. Rouquet, L. Aresu Vaccine 33 (2015) 5080–5086.

Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma L Marconato, S Comazzi, L Aresu, F Riondato, D Stefanello, R Ferrari, V Martini; The Veterinary Journal 2019

Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers. Marconato L, Aresu L, Stefanello D, Comazzi S, Martini V, Ferrari R, Riondato F, Rouquet N, Frayssinet P, Sabattini S.. J Immunother Cancer. 2019 Jun 7;7(1):146. doi: 10.1186/s40425-019-0624-y. PubMed PMID: 31174615

Here are the details of one of them:

Randomized, Placebo-Controlled, Double-Blinded Chemoimmunotherapy Clinical Trial in a Pet Dog Model of Diffuse Large B-cell Lymphoma

Laura Marconato, Patrick Frayssinet, Nicole Rouquet, Stefano Comazzi, Vito Ferdinando Leone, Paola Laganga, Federica Rossi, Massimo Vignoli, Lorenzo Pezzoli, Luca Aresu.

Clinical Cancer Research – Published 1 February 2014

This is a randomized, placebo-controlled, double-blinded chemo-immunotherapy clinical trial in a pet dog model of Diffuse Large B-cell Lymphoma (27 dogs) according to the described protocol.

These is a main results:

The general conclusion of this paper:

” Chemo-immunotherapy improved time to progression in dogs with indolent lymphoma.

Dogs mounting an immune response lived significantly longer.

There were no vaccine-related side effects.”

Fundamental research based on world wide collaborations, enabled the demonstration of safety and efficacy of this treatment on pets.
In addition, dozens of European veterinarian users have confirmed this efficiency, especially without combination with chemotherapy.
And to date, more than 500 pets with spontaneous cancers have been treated, since 2009.

If you want to learn more about the personalized immunotherapy, do not hesitate to contact us.